EMEA-000876-PIP07-15

Key facts

Invented name
Soliris
Active substance
Eculizumab
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0229/2016
PIP number
EMEA-000876-PIP07-15
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Prevention of delayed graft function after solid organ transplantation
Route(s) of administration
Intravenous use
Contact for public enquiries
Alexion Europe SAS
France
Tel. +33 147100606
Fax +33 147100611
E-mail: pip.enquiries@alxn.com
 
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating